guest ::
| Home > Publications database > EASIX-1 year and late mortality after allogeneic stem cell transplantation. > print |
| Home > Publications database > EASIX-1 year and late mortality after allogeneic stem cell transplantation. > print |
| 001 | 277771 | ||
| 005 | 20240229155023.0 | ||
| 024 | 7 | _ | |a 10.1182/bloodadvances.2022008617 |2 doi |
| 024 | 7 | _ | |a pmid:37477588 |2 pmid |
| 024 | 7 | _ | |a 2473-9529 |2 ISSN |
| 024 | 7 | _ | |a 2473-9537 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2023-01486 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kordelas, Lambros |0 0000-0003-3116-473X |b 0 |
| 245 | _ | _ | |a EASIX-1 year and late mortality after allogeneic stem cell transplantation. |
| 260 | _ | _ | |a Washington, DC |c 2023 |b American Society of Hematology |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1695116750_15140 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:C060# / 2023 Sep 26;7(18):5374-5381 |
| 520 | _ | _ | |a Patients with haematological malignancies who survive the first year after allogeneic stem cell transplantation (alloSCT) without relapse have a substantial risk of non-relapse mortality (NRM), and predictive markers are missing. The Endothelial Activation and Stress Index (EASIX) predicts endothelial complications and NRM early after alloSCT. We hypothesised that EASIX assessed 1 year after alloSCT in disease-free survivors may predict late NRM. Relapse-free survivors at one year after alloSCT were retrospectively studied in two independent cohorts (training cohort: n=610, merged validation cohort: n=852). EASIX determined one year after alloSCT was correlated with overall survival (OS), NRM, and relapse. Serum endothelial and inflammatory markers were measured in the training cohort and correlated with EASIX-1y. EASIX-1year predicted OS and NRM but not relapse risk in both, training and validation cohort in univariable and multivariable Cox regression analyses. Brier score and c-index analyses validated the univariable EASIX effects. There was no significant interaction between EASIX-1year and incidence of chronic GvHD on OS. EASIX-1year predicted outcome irrespective of pre-existing comorbidities. Principal causes of NRM in both, training and validation cohorts were infections with and without GvHD, as well as cardiovascular complications. EASIX-1y correlated with sCD141 and interleukin-18, but not with C-reactive protein, suppressor of tumorigenicity (ST)-2, angiopoietin-2, CXCL9 or CXCL8. EASIX-1year is the first validated predictor of late overall and non-relapse mortality. High-risk patients as defined by EASIX-1year might be considered for intensified surveillance and prophylactic measures. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Terzer, Tobias |0 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Gooley, Ted A |b 2 |
| 700 | 1 | _ | |a Davis, Chris |b 3 |
| 700 | 1 | _ | |a Sandmaier, Brenda M |0 0000-0002-9767-9739 |b 4 |
| 700 | 1 | _ | |a Sorror, Mohamed Lotfy |0 0000-0001-5260-1981 |b 5 |
| 700 | 1 | _ | |a Penack, Olaf |b 6 |
| 700 | 1 | _ | |a Schaeper, Nigel Dross Engelbert |b 7 |
| 700 | 1 | _ | |a Blau, Igor W |b 8 |
| 700 | 1 | _ | |a Beelen, Dietrich W |b 9 |
| 700 | 1 | _ | |a Radujkovic, Aleksandar |b 10 |
| 700 | 1 | _ | |a Dreger, Peter |b 11 |
| 700 | 1 | _ | |a Luft, Thomas |b 12 |
| 773 | _ | _ | |a 10.1182/bloodadvances.2022008617 |g p. bloodadvances.2022008617 |0 PERI:(DE-600)2876449-3 |n 18 |p 5374-5381 |t Blood advances |v 7 |y 2023 |x 2473-9529 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:277771 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-22 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BLOOD ADV : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BLOOD ADV : 2022 |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|